MedTrace Logo

Safety, Pharmacodynamic and Pharmacokinetic Effects of QAX576 in Healthy Volunteers.

NCT00417196 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-10-01

No results posted yet for this study

Summary

This study is designed to evaluate the safety, pharmacodynamic and pharmacokinetic effects of individual escalating intravenous doses of QAX576 in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

QAX576

Sponsors & Collaborators

Principal Investigators

  • Novartis · Investigator site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-12-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00417196 on ClinicalTrials.gov